Linearis Ventures

Founded in 2023, Linearis Ventures is a venture capital firm based in Montreal, Canada. It invests in innovative life sciences companies focused on preventing, detecting, and curing diseases through direct investments. The company brings together experts in biomarker discovery, drug development, healthcare innovators, and AI pioneers to support discoveries that transform healthcare systems and improve patient care.
https://crunchbase.com/organization/***
https://linkedin.com/company/***

Alexandre Le Bouthillier Ph.D

Co-Founder and General Partner

3 past transactions

Feldan Therapeutics

Venture Round in 2025
Feldan Therapeutics specializes in intracellular drug delivery using its patented Feldan Shuttle technology. This platform enables rapid, safe, and efficient transport of therapeutic agents into cells, with a focus on developing treatments for serious diseases such as skin and lung conditions.

Noetik

Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

Zilia

Zilia is a medtech company developing a non-invasive platform that uses imaging, spectroscopy and artificial intelligence to quantify biomarkers in the eye. The technology leverages the eye’s optical properties and its link to the vascular system and brain to enable early detection and monitoring of ocular and systemic health conditions. Its first product, Zilia Ocular, is a retinal camera designed to quantify oxygen saturation, a key biomarker in diseases such as glaucoma, diabetic retinopathy and age-related macular degeneration. By delivering actionable data on the eye’s metabolic activity, Zilia aims to improve prevention, diagnosis and management of these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.